21. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015) Authors: Sulkowski, Mark; Hezode, Christophe; Gerstoft, Jan; Vierling, John M; Mallolas, Josep; Pol, Stanislas; Kugelmas, Marcelo; Murillo, Abel; Weis, Nina; Nahass, Ronald; Shibolet, Oren; Serfaty, Lawrence; Bourliere, Marc; DeJesus, Edwin; Zuckerman, Eli; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy... Journal: Lancet Issue: Volume 385:Issue 9973(2015) Page Start: 1087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
22. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015) Authors: Sulkowski, Mark; Hezode, Christophe; Gerstoft, Jan; Vierling, John M; Mallolas, Josep; Pol, Stanislas; Kugelmas, Marcelo; Murillo, Abel; Weis, Nina; Nahass, Ronald; Shibolet, Oren; Serfaty, Lawrence; Bourliere, Marc; DeJesus, Edwin; Zuckerman, Eli; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy... Journal: Lancet Issue: Volume 385:Issue 9973(2015) Page Start: 1087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
23. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015) Authors: Sulkowski, Mark; Hezode, Christophe; Gerstoft, Jan; Vierling, John M; Mallolas, Josep; Pol, Stanislas; Kugelmas, Marcelo; Murillo, Abel; Weis, Nina; Nahass, Ronald; Shibolet, Oren; Serfaty, Lawrence; Bourliere, Marc; DeJesus, Edwin; Zuckerman, Eli; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy... Journal: Lancet Issue: Volume 385:Issue 9973(2015) Page Start: 1087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
24. Efficacy and Safety of Lersivirine Versus Etravirine for the Treatment of HIV-1 Infection in Patients with Prior Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Use and Evidence of NNRTI Resistance: A Randomized Phase 2B Trial. Issue 5 (September 2014) Authors: DeJesus, Edwin; Fätkenheuer, Gerd; Orrell, Catherine; Wang, Cunshan; Jones, James; Craig, Charles; Tawadrous, Margaret; Heera, Jayvant Journal: HIV clinical trials Issue: Volume 15:Issue 5(2014) Page Start: 209 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
25. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Issue 7 (July 2018) Authors: Daar, Eric S; DeJesus, Edwin; Ruane, Peter; Crofoot, Gordon; Oguchi, Godson; Creticos, Catherine; Rockstroh, Jürgen K; Molina, Jean-Michel; Koenig, Ellen; Liu, Ya-Pei; Custodio, Joseph; Andreatta, Kristen; Graham, Hiba; Cheng, Andrew; Martin, Hal; Quirk, Erin Journal: Lancet Issue: Volume 5:Issue 7(2018) Page Start: e347 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
26. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Issue 4 (April 2016) Authors: Gallant, Joel E; Daar, Eric S; Raffi, François; Brinson, Cynthia; Ruane, Peter; DeJesus, Edwin; Johnson, Margaret; Clumeck, Nathan; Osiyemi, Olayemi; Ward, Doug; Morales-Ramirez, Javier; Yan, Mingjin; Abram, Michael E; Plummer, Andrew; Cheng, Andrew K; Rhee, Martin S Journal: Lancet Issue: Volume 3:Issue 4(2016) Page Start: e158 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
27. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Issue 10246 (25th July 2020) Authors: Mayer, Kenneth H; Molina, Jean-Michel; Thompson, Melanie A; Anderson, Peter L; Mounzer, Karam C; De Wet, Joss J; DeJesus, Edwin; Jessen, Heiko; Grant, Robert M; Ruane, Peter J; Wong, Pamela; Ebrahimi, Ramin; Zhong, Lijie; Mathias, Anita; Callebaut, Christian; Collins, Sean E; Das, Moupali; McCall... Journal: Lancet Issue: Volume 396:Issue 10246(2020) Page Start: 239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
28. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Issue 6 (June 2020) Authors: Orkin, Chloe; DeJesus, Edwin; Sax, Paul E; Arribas, Jose R; Gupta, Samir K; Martorell, Claudia; Stephens, Jeffrey L; Stellbrink, Hans-Jurgen; Wohl, David; Maggiolo, Franco; Thompson, Melanie A; Podzamczer, Daniel; Hagins, Debbie; Flamm, Jason A; Brinson, Cynthia; Clarke, Amanda; Huang, Hailin; Ac... Journal: Lancet Issue: Volume 7:Issue 6(2020) Page Start: e389 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
29. Idx184 in Combination with Pegylated Interferon-α2A and Ribavirin for 2 Weeks in Treatment-Naive Patients with Chronic Hepatitis C. Issue 6 (August 2013) Authors: Lalezari, Jacob; Box, Terry; O'Riordan, William; Mehra, Purvi; Nguyen, Tuan; Poordad, Fred; DeJesus, Edwin; Kwo, Paul; Godofsky, Eliot; Lawrence, Shannon; Dubuc-Patrick, Gloria; Chen, Jie; McCarville, Joseph; Pietropaolo, Keith; Zhou, Xiao-Jian; Sullivan-Bólyai, John; Mayers, Douglas Journal: Antiviral therapy Issue: Volume 18:Issue 6(2013) Page Start: 755 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
30. Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial. Issue 6 (June 2021) Authors: Molina, Jean-Michel; Yazdanpanah, Yazdan; Afani Saud, Alejandro; Bettacchi, Christopher; Chahin Anania, Carolina; DeJesus, Edwin; Olsen Klopfer, Stephanie; Grandhi, Anjana; Eves, Karen; Robertson, Michael N; Correll, Todd; Hwang, Carey; Hanna, George J; Sklar, Peter Journal: Lancet Issue: Volume 8:Issue 6(2021) Page Start: e324 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗